• Most Popular
  • Most Shared

Ranbaxy gets tentative US okay for generic allergy drug

Thu May 17, 2007 10:20am EDT

Stocks

   

Regulatory News

May 17 (Reuters) - India-based Ranbaxy Laboratories Ltd.'s (RANB.BO) U.S. unit said it received tentative regulatory approval to market generic Fexofenadine Hydrochloride tablets for seasonal allergic rhinitis.

Ranbaxy said the U.S. regulators have tentatively approved 30 mg, 60 mg, and 180 mg dosages of the tablet.

(Reporting by Jennifer Robin Raj in Bangalore)

((Editing by Anil Kumar; Reuters Messaging: aruna.jennifer.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: RANBAXY APPROVAL/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS1810
Regulatory News


More from Reuters

Jobless claims at lowest since July 2008

WASHINGTON (Reuters) - The number of workers filing new applications for jobless benefits fell last week to the lowest level in about 17 months, according to U.S. government data on Thursday.

» More Top News
Traders work in the pits at the The New York Mercantile Exchange, November 7, 2007. REUTERS/Brendan McDermid

Calling the market

A spectacular credit bust, two devastating stock market crashes ... the smart call this decade was to play it safe.  Full Article 

Global Markets
People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid
Rolfe Winkler:

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article 

    Commentary